Skip to main content

hypericin

Generic: hypericin

hypericin: 4 clinical trials tracked.

hypericin evidence translation

What we can confirm

4 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about hypericin, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trial Registry Records (4)

A Confirmatory Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Topical HyBryte™ (Hypericin Sodium) and Visible-Light Activation for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

NCT06470451Registry updated 2026-07-13·Phase 3·SNGX
Terminated

Primary endpoint: Number of Participants with a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) score

InterventionalRandomizedquadruple70 enrolledStarted 2025-01Completion 2026-0517 sites · United StatesSoligenix

Pilot Study of HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

NCT06149247Registry updated 2025-08-20·Phase 2·SNGX
Completed

Primary endpoint: Number of Participants With a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) Score

InterventionalRandomizedopen10 enrolledStarted 2023-12Completion 2024-061 site · United StatesSoligenix

Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light

NCT05872854Registry updated 2026-02-09·Phase 2
Completed

Primary endpoint: Number of Treatment Responses of Index Lesions

Interventionalopen10 enrolledStarted 2023-08Completion 2025-121 site · United StatesEllen Kim, MD

Phase 2 Study Evaluating SGX302 (Synthetic Hypericin) in the Treatment of Mild-to-Moderate Psoriasis

NCT05442190Registry updated 2026-08-13·Phase 2·SNGX
Completed

Primary endpoint: Number of patients that achieve a 0 or 1 score using the 5-point Investigator's Global Assessment scale

InterventionalRandomizedquadruple15 enrolledStarted 2022-12Completion 2025-111 site · United StatesSoligenix